SCHEMBL6023644

SCHEMBL6023644

Cc1cccc(C)c1N1c2ccccc2C(C(=O)O)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
MAPT P10636 1/20 0.39
GAA P10253 3/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ATM Q13315 1/20 0.38
AMPD2 Q01433 1/20 0.38
EGFR P00533 1/20 0.38
SRC P12931 1/20 0.38
TSHR P16473 1/20 0.37
NOTUM Q6P988 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MGLL Q99685 1/20 0.36
ANPEP P15144 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6024230 0.78 HDAC4 (0.42) HDAC4HDAC7HDAC5MAPTGAA
SCHEMBL31613807 0.75 HDAC4 (0.66) HDAC4HDAC7HDAC5MAPTGAA
SCHEMBL2989515 0.75 HDAC4 (0.66) HDAC4HDAC7HDAC5MAPTGAA
Hydrochloric Acid SCHEMBL2982836 0.74 HDAC4 (0.64) HDAC4HDAC7HDAC5MAPTGAA
SCHEMBL9622137 0.73 MYC (0.44) HDAC4GAAALDH1A1TP53TSHR
SCHEMBL3769010 0.71 HDAC4 (0.51) HDAC4HDAC7HDAC5MAPTGAA
Biphenyl SCHEMBL2987647 0.71 HDAC4 (0.60) HDAC4HDAC7HDAC5MAPTGAA
SCHEMBL9449453 0.70 MYC (0.50) HDAC4HDAC7HDAC5GAATP53
SCHEMBL6024353 0.70 EDNRA (0.45) MAPTGAAALDH1A1NOTUMSMN1; SMN2
SCHEMBL10355854 0.70 EDNRA (0.50) HDAC4HDAC7HDAC5ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1353908-B1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN INC (US) 2006-03-08 EP disclosed
EP-1353908-A4 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN INC (US) 2004-01-28 EP disclosed
EP-1353908-A1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN, INC. (US) 2003-10-22 EP disclosed
WO-2002059096-A1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN, INC. (US) 2002-08-01 WO disclosed
US-6410732-B2 FORMATION OF BOND BETWEEN NITROGEN ATOM OF ACRIDAN RING AND CARBON ATOM OF ANOTHER AROMATIC OR HETEROAROMATIC RING COMPOUND; ASSAYS FOR PEROXIDASE ENZYMES AND ENZYME INHIBITORS AND IN ASSAYS EMPLOYING ENZYME-LABELED SPECIFIC BINDING PAIRS LUMIGEN, INC. 2002-06-25 US disclosed
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives LUMIGEN, INC. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives ALDH3A1, AADAC, SPR HDAC4 2828/4885HDAC7 3028/4885HDAC5 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.